<code id='B7EA121ADA'></code><style id='B7EA121ADA'></style>
    • <acronym id='B7EA121ADA'></acronym>
      <center id='B7EA121ADA'><center id='B7EA121ADA'><tfoot id='B7EA121ADA'></tfoot></center><abbr id='B7EA121ADA'><dir id='B7EA121ADA'><tfoot id='B7EA121ADA'></tfoot><noframes id='B7EA121ADA'>

    • <optgroup id='B7EA121ADA'><strike id='B7EA121ADA'><sup id='B7EA121ADA'></sup></strike><code id='B7EA121ADA'></code></optgroup>
        1. <b id='B7EA121ADA'><label id='B7EA121ADA'><select id='B7EA121ADA'><dt id='B7EA121ADA'><span id='B7EA121ADA'></span></dt></select></label></b><u id='B7EA121ADA'></u>
          <i id='B7EA121ADA'><strike id='B7EA121ADA'><tt id='B7EA121ADA'><pre id='B7EA121ADA'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:Wikipedia    Page View:95682
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

          PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          JPM 2024: Verve Therapeutics looks to mainstream genome editing

          VerveTherapeuticsCEOSekarKathiresanVerveSANFRANCISCO—Thepromiseofgenomeeditinghasgivenrisetopotentia